Related Experiment Video

Updated: Apr 21, 2026

Semiconductor Sequencing for Preimplantation Genetic Testing for Aneuploidy
09:03

Semiconductor Sequencing for Preimplantation Genetic Testing for Aneuploidy

Published on: August 25, 2019

8.8K

Newborn screening and related policy against Phenylketonuria in China

Lin Mei1, Peipei Song2, Lingzhong Xu1

  • 1Department of Health Care Management and Maternal and Child Health, Shandong University, Ji'nan, Shandong, China;

Intractable & Rare Diseases Research
|October 25, 2014
PubMed

Insights

Phenylketonuria (PKU), an inherited metabolic disorder, is effectively controlled in China through newborn screening programs. Laws and regulations have improved screening, though challenges remain for future enhancements.

Area of Science:

  • Medical Genetics
  • Public Health Policy
  • Metabolic Disorders

Background:

  • Phenylketonuria (PKU) is a preventable inherited metabolic disease with an incidence of 1/11,144 in China.
  • Newborn screening is a crucial method for controlling PKU.
  • China initiated its national newborn screening program in 1981, with increasing screening rates annually.

Purpose of the Study:

  • To review the current legal and regulatory landscape of newborn screening for PKU in China.
  • To assess the impact of these laws and regulations on the improvement of China's newborn screening program.
  • To identify successful measures and potential challenges in PKU screening implementation.

Main Methods:

  • Review of existing laws and regulations pertaining to newborn screening for PKU in China.
  • Analysis of implemented measures, including government initiatives, follow-up services, and financial coverage.
  • Evaluation of the effectiveness of these measures in different regions.

Main Results:

  • Government-led measures, dedicated follow-up services, and financial support have demonstrated positive outcomes in various regions.
  • The implemented legal and regulatory framework has contributed to the enhancement of China's PKU newborn screening program.
  • Regional successes offer valuable insights for broader implementation.

Conclusions:

  • China's newborn screening program for PKU has advanced due to supportive laws and regulations.
  • Challenges persist, indicating areas for future development.
  • Enhanced prenatal health examinations and national financial support are crucial for the future of PKU newborn screening.

Keywords:
Phenylketonuria (PKU)incidenceinherited metabolic diseasemeasures and regulationsnewborn screening

More Related Videos

Pre-Implantation Genetic Testing for Aneuploidy on a Semiconductor Based Next-Generation Sequencing Platform09:30

Pre-Implantation Genetic Testing for Aneuploidy on a Semiconductor Based Next-Generation Sequencing Platform

Published on: August 17, 2022

2.1K
Protocol and Guidelines for Point-of-Care Lung Ultrasound in Diagnosing Neonatal Pulmonary Diseases Based on International Expert Consensus06:15

Protocol and Guidelines for Point-of-Care Lung Ultrasound in Diagnosing Neonatal Pulmonary Diseases Based on International Expert Consensus

Published on: March 6, 2019

53.2K

Related Concept Videos

Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
1.0K
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
391
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
395
Genetic Screens02:46

Genetic Screens

Genetic screens are tools used to identify genes and mutations responsible for phenotypes of interest. Genetic screens help identify individuals or a group of people at risk of developing  genetic diseases and help them with early intervention, targeted therapy, and reproductive options.
Forward genetic screens
Forward or “classical” genetic screens involve creating random mutations in an organism’s DNA using radiation, mutagens, or insertion of additional bases, which...
4.6K
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
532
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
918